Compare TS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TS | UTHR |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 23.1B |
| IPO Year | 2002 | 1999 |
| Metric | TS | UTHR |
|---|---|---|
| Price | $56.12 | $485.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $58.80 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.0M | 491.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 13.07 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $1.53 | $6.39 |
| Revenue Next Year | $3.59 | $14.18 |
| P/E Ratio | ★ $12.59 | $36.40 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $33.71 | $409.15 |
| 52 Week High | $64.60 | $609.35 |
| Indicator | TS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 40.53 |
| Support Level | $54.39 | $463.88 |
| Resistance Level | $58.72 | $487.91 |
| Average True Range (ATR) | 1.10 | 10.69 |
| MACD | -0.07 | -1.30 |
| Stochastic Oscillator | 50.65 | 36.23 |
Tenaris SA is engaged in the manufacture and supply of steel pipe products and related services for the energy industry and other industrial applications. The company has one reportable segment, Tubes, which includes the production and sale of steel tubular products such as OCTG, line pipe, and mechanical and structural tubes, mainly for the oil and gas industry. It operates an integrated network of manufacturing, research, and service facilities across the Americas, Europe, the Middle East, Asia, and Africa.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.